BTK and myeloid sarcoma: Furthermore, leptomeningeal inflammation, which was associated with poor clinical outcomes in MS, has been modelled in experimental autoimmune encephalomyelitis (EAE) mice.27 Mice treated with evobrutinib showed a significant improvement in meningeal inflammation, compared with vehicle, exhibiting a 30% reduction and a 5% increase, respectively.27 Remibrutinib (Novartis) treatment in EAE models strongly reduced B-cell-dependent inflammation and exhibited BTK occupancy in the brain and peripheral immune system.28